SINTX Technologies Inc (SINT)
1.74
+0.17 +10.83%
NASDAQ
Dec 13, 16:58
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 0.532M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -7.704 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -3.499M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 12.72% |
| Profit Margin (Quarterly) | -835.8% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0% |
| Price and Valuation | |
| Market Cap | 4.235M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 3.690 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 0.7025 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | 0.0035 |
| Free Cash Flow (Quarterly) | -1.469M |
| Return on Equity (TTM) | Upgrade |
View All SINT News
News
-
WireHeadlineTime (ET)
-
SA Breaking News11/18 07:34
-
Globe Newswire11/18 07:30
-
Yahoo11/14 09:08
-
SA Breaking News11/13 09:10
-
SA Breaking News11/13 08:34
-
SA Breaking News11/04 12:48
-
SA Breaking News11/04 11:01
-
SA Breaking News10/28 10:59
-
SA Breaking News09/24 12:51
-
SA Breaking News09/18 11:02
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.sintx.com
- Investor Relations URL: http://investors.amedica.com/
- HQ State/Province: Utah
- Sector: Healthcare
- Industry: Medical Devices
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Nov. 21, 2018
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: SINTX Technologies Inc is a commercial biomaterial company, focuses on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The company markets and sells its products to surgeons and hospitals directly, as well as through a network of independent sales distributors. It derives its revenue primarily from the sale of spinal fusion and fixation devices and related products used in the treatment of spine disorders.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 1.74 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- SINT Tweets Stocktwits
Advertisement
